Acta Veterinaria et Zootechnica Sinica ›› 2022, Vol. 53 ›› Issue (1): 200-208.doi: 10.11843/j.issn.0366-6964.2022.01.020

• PREVENTIVE VETERINARY MEDICINE • Previous Articles     Next Articles

A Case Report of Feline Infectious Peritonitis based on High-throughput Sequencing Diagnosis and Small-molecule Nucleoside Analogues Treatment

LI Ben1, GUO Fuqiang2, WANG Weiwei1, JIN Ningyi3, JIN Qiushi5, MI Zhiqiang4, LI Chang3*, WANG Maopeng1*   

  1. 1. Institute of Virology, Wenzhou University, Wenzhou 325035, China;
    2. Ruipeng Pet Hospital, Shenzhen 518000, China;
    3. Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China;
    4. State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China;
    5. Centre of Imaging Diagnosis and Interventional Treatment, Mudanjiang Cardiovascular Disease Hospital of Heilongjiang Province, Mudanjiang 157001, China
  • Received:2021-04-06 Online:2022-01-23 Published:2022-01-26

Abstract: Feline infectious peritonitis (FIP) is a highly lethal infectious disease caused by coronavirus and characterized by severe abdominal cavity inflammation. However, there is no approved standard method for the diagnosis or treatment of pathogen. Therefore, this study describes the diagnosis and treatment process from a case report of feline infectious peritonitis and explores reasonable diagnosis and treatment methods for the disease. High-throughput sequencing technology, clinical symptoms, biochemical analysis, blood routine and etc. were comprehensively used to diagnose this case, to evaluate the treatment effect of the antiviral drug GS-441524 with albumin/globulin ratio and fSAA level, and to monitore the sequelae. Results showed that high-throughput sequencing technology can be applied to the diagnosis of FIP. After high-dose drug treatment, the clinical symptoms were significantly improved, the albumin/globulin ratio and fSAA were restored to normal at 8 weeks, and the discharge standards were met at 10 weeks. No signs of disease recurrence were found during the 16-week review. The successful treatment of this case proves the potential of high-throughput sequencing technology in veterinary clinical diagnosis, and the effectiveness of GS-441524 in the treatment of critical cases. The serum albumin/globulin ratio (≥0.6) and fSAA (<5 μg·mL-1) can be a clinical indicator to evaluate the therapeutic effect.

Key words: feline infectious peritonitis, feline coronavirus, high-throughput sequencing technology, GS-441524

CLC Number: